Patents by Inventor Francisco J. Quintana
Francisco J. Quintana has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240151709Abstract: The present application relates to compositions and methods for tracing cell networks, e.g., for investigation of cell interactions in the CNS with single cell resolution.Type: ApplicationFiled: March 1, 2022Publication date: May 9, 2024Inventors: Francisco J. Quintana, Michael A. Wheeler, Iain C. Clark
-
Publication number: 20220323521Abstract: Described herein are microbial probiotics that, in response to metabolite extracellular ATP (eATP) produced in the microenvironment of inflamed tissues detected, e.g., via an engineered mammalian P2Y2 receptor, secrete an anti-inflammatory protein, e.g., IL-2, IL-10, or the CD39-like eATP-degrading enzyme apyrase. Thus, provided herein is an isolated Saccharomyces cell (or cells, e.g., a population of such cells) that has been engineered to express one, two, or all three exogenous proteins selected from: (I) a mammalian P2Y purinoceptor 2 (P2Y2) protein, preferably human P2Y2; 15 (ii) a mutant Gpa1 protein comprising at least 5 C-terminal residues from a mammalian G alpha, preferably Gai3, wherein the mutant Gpa1 protein couples the P2Y2 protein to the yeast mating pathway; and (iii) an anti-inflammatory protein.Type: ApplicationFiled: August 26, 2020Publication date: October 13, 2022Inventors: Francisco J. Quintana, Benjamin M. Scott, Sergio G. Peisajovich, Belinda S. W. Chang
-
Patent number: 11253589Abstract: Methods for identifying compounds that modulate the generation of regulatory T cells (Treg) in vivo and in vitro, i.e., compounds that act on the transcription factors that increase or decrease expression of Foxp3.Type: GrantFiled: October 12, 2017Date of Patent: February 22, 2022Assignee: The Brigham and Women's Hospital, Inc.Inventors: Howard Weiner, Francisco J. Quintana
-
Publication number: 20200069731Abstract: Embodiments of various aspects described herein are directed to methods and compositions for producing a tolerogenic or immunosuppressive dendritic cell. In particular, an immunosuppressive dendritic cell can be produced by contacting a dendritic cell with an agent that stimulates the IL-27/ectonucleotidase CD39 axis signaling. In some embodiments, the methods and/or compositions described herein can be used for treating an autoimmune disease or disorder, e.g., but not limited to multiple sclerosis (MS) and type 1 diabetes.Type: ApplicationFiled: September 30, 2019Publication date: March 5, 2020Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.Inventors: Francisco J. QUINTANA, Ivan D. MASCANFRONI
-
Patent number: 10555919Abstract: Methods for treating, or reducing risk of developing, seasonal worsening of multiple sclerosis (MS) in a subject who has MS, comprising administering a melatonin agonist to a subject.Type: GrantFiled: November 12, 2015Date of Patent: February 11, 2020Assignee: The Brigham and Women's Hospital, Inc.Inventors: Mauricio Farez, Francisco J. Quintana, Jorge Correale
-
Patent number: 10426794Abstract: Embodiments of various aspects described herein are directed to methods and compositions for producing a tolerognic or immunosuppressive dendritic cell. In particular, an immunosuppressive dendritic cell can be produced by contacting a dendritic cell with an agent that stimulates the IL 27/ectonucleotidase CD39 axis signaling. In some embodiments, the methods and/or compositions described herein can be used for treating an autoimmune disease or disorder, e.g., but not limited to multiple sclerosis (MS) and type 1 diabetes.Type: GrantFiled: April 11, 2014Date of Patent: October 1, 2019Assignee: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.Inventors: Francisco J. Quintana, Ivan D. Mascanfroni
-
Patent number: 10226517Abstract: A method of treating a T cell-mediated inflammatory autoimmune disease by administering to an individual in need thereof an immunogenic composition comprising a recombinant construct of a nucleic acid sequence encoding heat shock protein 90 (HSP 90), or an active fragment thereof, wherein the nucleic acid sequence is operatively linked to one or more transcription control sequences. The disease is other than insulin dependent diabetes mellitus (IDDM) or rheumatoid arthritis. The administering of the immunogenic composition results in a shift of the immune response to a Th2 response, thereby treating the disease.Type: GrantFiled: April 19, 2018Date of Patent: March 12, 2019Assignee: Alma Bio TherapeuticsInventors: Irun R. Cohen, Francisco J. Quintana, Pnina Carmi, Felix Mor
-
Publication number: 20180236052Abstract: A method of treating a T cell-mediated inflammatory autoimmune disease by administering to an individual in need thereof an immunogenic composition comprising a recombinant construct of a nucleic acid sequence encoding heat shock protein 90 (HSP 90), or an active fragment thereof, wherein the nucleic acid sequence is operatively linked to one or more transcription control sequences. The disease is other than insulin dependent diabetes mellitus (IDDM) or rheumatoid arthritis. The administering of the immunogenic composition results in a shift of the immune response to a Th2 response, thereby treating the disease.Type: ApplicationFiled: April 19, 2018Publication date: August 23, 2018Inventors: Irun R. Cohen, Francisco J. Quintana, Pnina Carmi, Felix Mor
-
Patent number: 9974843Abstract: A method of treating a T cell-mediated inflammatory autoimmune disease by administering to an individual in need thereof an immunogenic composition comprising a recombinant construct of a nucleic acid sequence encoding heat shock protein 90 (HSP 90), or an active fragment thereof, wherein the nucleic acid sequence is operatively linked to one or more transcription control sequences. The disease is other than insulin dependent diabetes mellitus (IDDM) or rheumatoid arthritis. The administering of the immunogenic composition results in a shift of the immune response to a Th2 response, thereby treating the disease.Type: GrantFiled: February 1, 2016Date of Patent: May 22, 2018Assignee: Alma Bio TherapeuticsInventors: Irun R. Cohen, Francisco J. Quintana, Pnina Carmi, Felix Mor
-
Publication number: 20180125971Abstract: Methods for identifying compounds that modulate the generation of regulatory T cells (Treg) in vivo and in vitro, i.e., compounds that act on the transcription factors that increase or decrease expression of Foxp3.Type: ApplicationFiled: October 12, 2017Publication date: May 10, 2018Inventors: Howard Weiner, Francisco J. Quintana
-
Patent number: 9927437Abstract: As described herein, lactosylceramide (LacCer) levels are up-regulated in the CNS during chronic experimental autoimmune encephalomyelitis (EAE), an experimental model of multiple sclerosis (MS). LacCer acts in an autocrine manner to trigger transcriptional programs that promote the recruitment and activation of CNS infiltrating monocytes and microglia, and neurodegeneration. In addition, increased B4GALT6 expression and LacCer levels were detected in CNS MS lesions in human patients. Finally, the inhibition of LacCer synthesis suppressed local CNS innate immunity and neurodegeneration in EAE, and interfered with the activation of human astrocytes in vitro. Thus, B4GALT6 is a therapeutic target for MS and other neuroinflammatory disorders.Type: GrantFiled: December 12, 2014Date of Patent: March 27, 2018Assignee: The Brigham and Women's Hospital, Inc.Inventors: Francisco J. Quintana, Lior Mayo, Howard Weiner, Reza Halse
-
Publication number: 20180071376Abstract: Methods and compositions for increasing the number and/or activity of regulatory T cells (Tregs) in vivo and in vitro, to induce tolerance to diabetogenic autoantigens.Type: ApplicationFiled: March 23, 2016Publication date: March 15, 2018Inventors: Ada Yeste Bornal, Francisco J. Quintana
-
Patent number: 9895440Abstract: Methods for increasing the numbers of regulatory T cells (Treg), e.g., in a population of T cells or in a patient.Type: GrantFiled: November 26, 2014Date of Patent: February 20, 2018Assignee: The Brigham and Women's Hospital, Inc.Inventors: Howard Weiner, Francisco J. Quintana
-
Publication number: 20170333371Abstract: Methods for treating, or reducing risk of developing, seasonal worsening of multiple sclerosis (MS) in a subject who has MS, comprising administering a melatonin agonist to a subject.Type: ApplicationFiled: November 12, 2015Publication date: November 23, 2017Applicant: The Brigham and Women's Hospital, Inc.Inventors: Mauricio Farez, Francisco J. Quintana, Jorge Correale
-
Publication number: 20170000865Abstract: A method of treating a T cell-mediated inflammatory autoimmune disease by administering to an individual in need thereof an immunogenic composition comprising a recombinant construct of a nucleic acid sequence encoding heat shock protein 90 (HSP 90), or an active fragment thereof, wherein the nucleic acid sequence is operatively linked to one or more transcription control sequences. The disease is other than insulin dependent diabetes mellitus (IDDM) or rheumatoid arthritis. The administering of the immunogenic composition results in a shift of the immune response to a Th2 response, thereby treating the disease.Type: ApplicationFiled: February 1, 2016Publication date: January 5, 2017Inventors: Irun R. Cohen, Francisco J. Quintana, Pnina Carmi, Felix Mor
-
Publication number: 20160313324Abstract: As described herein, lactosylceramide (LacCer) levels are up-regulated in the CNS during chronic experimental autoimmune encephalomyelitis (EAE), an experimental model of multiple sclerosis (MS). LacCer acts in an autocrine manner to trigger transcriptional programs that promote the recruitment and activation of CNS infiltrating monocytes and microglia, and neurodegeneration. In addition, increased B4GALT6 expression and LacCer levels were detected in CNS MS lesions in human patients. Finally, the inhibition of LacCer synthesis suppressed local CNS innate immunity and neurodegeneration in EAE, and interfered with the activation of human astrocytes in vitro. Thus, B4GALT6 is a therapeutic target for MS and other neuroinflammatory disorders.Type: ApplicationFiled: December 12, 2014Publication date: October 27, 2016Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.Inventors: Francisco J. Quintana, Lior Mayo, Howard Weiner, Reza Halse
-
Patent number: 9283265Abstract: A method of treating a T cell-mediated inflammatory autoimmune disease by administering to an individual in need thereof an immunogenic composition comprising a recombinant construct of a nucleic acid sequence encoding heat shock protein 90 (HSP 90), or an active fragment thereof, wherein the nucleic acid sequence is operatively linked to one or more transcription control sequences. The disease is other than insulin dependent diabetes mellitus (IDDM) or rheumatoid arthritis. The administering of the immunogenic composition results in a shift of the immune response to a Th2 response, thereby treating the disease.Type: GrantFiled: October 6, 2014Date of Patent: March 15, 2016Assignee: Alma Bio TherapeuticsInventors: Irun R. Cohen, Francisco J. Quintana, Pnina Carmi, Felix Mor
-
Publication number: 20160058792Abstract: Embodiments of various aspects described herein are directed to methods and compositions for producing a tolerogenic or immunosuppressive dendritic cell. In particular, an immunosuppressive dendritic cell can be produced by contacting a dendritic cell with an agent that stimulates the IL 27/ectonucleotidase CD39 axis signaling. In some embodiments, the methods and/or compositions described herein can be used for treating an autoimmune disease or disorder, e.g., but not limited to multiple sclerosis (MS) and type 1 diabetes.Type: ApplicationFiled: April 11, 2014Publication date: March 3, 2016Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.Inventors: Francisco J. QUINTANA, Ivan D. MASCANFRONI
-
Patent number: 9267945Abstract: The present invention relates to methods and kits for diagnosing multiple sclerosis (MS) in a subject. Particularly, the present invention relates to methods and kits for diagnosing a subtype of MS in a subject, the subtype selected from relapsing-remitting MS (RRMS), secondary progressive MS (SPMS), primary progressive MS (PPMS) and a pathologic sub-type of MS lesions selected from Pattern I and Pattern II MS lesion.Type: GrantFiled: November 12, 2009Date of Patent: February 23, 2016Assignees: Yeda Research and Development Co. Ltd., The Brigham and Women's HospitalInventors: Howard L. Weiner, Irun R. Cohen, Francisco J. Quintana
-
Publication number: 20150238583Abstract: A method of treating a T cell-mediated inflammatory autoimmune disease by administering to an individual in need thereof an immunogenic composition comprising a recombinant construct of a nucleic acid sequence encoding heat shock protein 90 (HSP 90), or an active fragment thereof, wherein the nucleic acid sequence is operatively linked to one or more transcription control sequences. The disease is other than insulin dependent diabetes mellitus (IDDM) or rheumatoid arthritis. The administering of the immunogenic composition results in a shift of the immune response to a Th2 response, thereby treating the disease.Type: ApplicationFiled: October 6, 2014Publication date: August 27, 2015Inventors: Irun R. Cohen, Francisco J. Quintana, Pnina Carmi, Felix Mor